🔎 Trials Near Me

ホーム › うつ病 › ジョージア州

ジョージア州におけるうつ病の臨床試験

ジョージア州内の拠点で、うつ病に関する28件の研究が参加者を募集しています。

ジョージア州内の都市

公式研究テキスト(英語)

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  • CenExel iResearch, LLC, Decatur
  • AGILE Clinical Research Trials, LLC, Sandy Springs
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07775300

Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

  • Emory Healthcare, Atlanta
被験者募集中
22歳〜85歳 · 全性別 · 2026/09/29更新 · NCT07594483

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

  • Evergreen Clinical Trials, Norcross
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07621237

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  • Psych Atlanta, Marietta
被験者募集中第3相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06793397

JAK Signaling in Depression and Cognition in Male Football Players

  • Emory Clinic, Emory University Hospital, Atlanta
  • Emory School Of Medicine, Atlanta
  • Emory University, Atlanta
被験者募集中第2相健康なボランティア歓迎
30歳〜55歳 · 男性 · 2026/09/24更新 · NCT07608796

Brexanolone Lifting Outcomes Of Moms

  • Lipocine Investigational Site, Decatur
被験者募集中第3相
15歳〜45歳 · 女性 · 2026/09/16更新 · NCT07822321

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  • Emory University, Atlanta
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07002034

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  • Seaport Investigator Site, Atlanta
  • Seaport Investigator Site, Decatur
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/09/14更新 · NCT07065240

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  • Delricht Research, Atlanta
  • Emory University Brain Health Center, Atlanta
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/08更新 · NCT07076407

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

  • Emory University, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06713616

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

  • Draig Clinical Site, Decatur
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/02更新 · NCT07610473

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

  • Draig Clinical Site, Atlanta
  • Draig Clinical Site, Decatur
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/08/26更新 · NCT07300969

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06911112

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  • CenExel iResearch, LLC, Decatur
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/08/06更新 · NCT07412756

E-Mindfulness Approaches for Living After Breast Cancer

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • 他3件
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  • Advanced Discovery Research, Atlanta
  • Synexus - Atlanta, Atlanta
  • Psych Atlanta, Pc, Marietta
  • 他1件
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/08/03更新 · NCT06775379

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

  • CenExcel iResearch LLC /ID# 228695, Decatur
  • Denali Health Atlanta, LLC /ID# 278167, Stone Mountain
被験者募集中第3相
10歳〜17歳 · 全性別 · 2026/07/27更新 · NCT04777357

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/24更新 · NCT06966401

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  • Emory University, Atlanta
  • Medical College of Georgia, Augusta University, Augusta
  • Psych Atlanta, Marietta
被験者募集中
18歳以上 · 全性別 · 2026/06/15更新 · NCT03887715

Mechanisms of Behavioral Activation (BA)

  • Emory University, Atlanta
  • Facility for Education and Research in Neuroscience (FERN), Atlanta
  • Child and Adolescent Mood Program (CAMP), Atlanta
被験者募集中健康なボランティア歓迎
15歳〜17歳 · 全性別 · 2026/06/01更新 · NCT05548244

Inflammation and Depression in People With HIV

  • Grady Memorial Hospital, Atlanta
  • Emory University Hospital, Atlanta
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/28更新 · NCT05849038

Assessing Improvements in Mood and Sleep Trial

  • Augusta University, Augusta
被験者募集中
55歳以上 · 全性別 · 2026/05/19更新 · NCT06639477

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  • CenExcel, Decatur
  • CenExel, Savannah
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/11更新 · NCT06524830

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

  • Savannah VA Clinic, Savannah
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/04/29更新 · NCT07280065

Dopaminergic Therapy for Anhedonia - 2

  • Emory University Hospital, Atlanta
被験者募集中第4相
25歳〜55歳 · 全性別 · 2026/01/28更新 · NCT06075771

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

  • Grady Health System, Atlanta
被験者募集中
18歳〜64歳 · 全性別 · 2026/01/07更新 · NCT02604277

Brain Stimulation and Decision-making

  • Emory University, Atlanta
被験者募集中健康なボランティア歓迎
18歳〜50歳 · 全性別 · 2025/12/10更新 · NCT04099056

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

  • Clinical Research Site, Atlanta
被験者募集中第4相
18歳〜65歳 · 全性別 · 2025/01/23更新 · NCT06223880

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。